Bladder Preservation Therapy in combination with Atezolizumab and Radiation Therapy for invasive bladder cancer, a phase II, open-label, multicenter study - BPT-ART

ishiyama Hiroyuki0 sites45 target enrollmentDecember 20, 2018

ConditionsBladder cancer

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: Bladder cancer
Sponsor: ishiyama Hiroyuki
Enrollment: 45
Status: Active, not recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

December 20, 2018

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

ishiyama Hiroyuki

Eligibility Criteria

Inclusion Criteria

•1\. Histologically confirmed UC of the bladder by TURBT within 90 days prior to study registration. Patients who received 2nd\-TURBT, the date of surgery within 90 days prior to study registration (Histologically confirmed by TURBT diagnosis of UC of the bladder within 150 days prior to study registration). 2\. Histologically confirmed cT1\-3N0M0 (UICC/AJCC 8th edition) invasive bladder cancer 1\) Tumor stage cT1N0M0 Patients must satisfy one of more of the following: a. Multiple T1 carcinoma (2 and more) b. Residual T1 lesion by 2nd\-TUR c. T1 carcinoma with CIS d. BCG\-resistant T1 carcinoma e. BCG\-intolerant recurrent T1 carcinoma 2\) Tumor stage cT2\-3N0M0 Maximum lesion diameter 5 cm and more 3\. Life expectancy 3 years and more 4\. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 5\. The following laboratory results obtained within 14 days prior to the first dose of Atezolizumab. a. WBC counts 2500/microliter and more b. ANC 1500 cells/microliter and more c. Lymphocyte count 300/microliter and more d. Platelet count 100,000/microliter and more e. Hemoglobin 9\.0 gram/deciliter and more f. AST, ALT and alkaline phosphatase 2\.5\-fold or less the upper limit of normal (ULN) g. Total bilirubin 1\.0\-fold or less ULN h. Serum creatinine 2\.5\-fold or less ULN or Calculated creatinine clearance 30 milliliter/min and more (Cockcroft\-Gault formula) i. PTT/PT 1\.5\-fold or less ULN or PT\-INR 1\.7\-fold or less ULN 6\. Women of childbearing potential must agree to remain abstinent or use contraceptive methods that result in a failure rate of less than 1% per year during the treatment period and for at least 5 months after the last dose of investigational agent. 7\. Men has a partner as woman of childbearing potential must agree to use contraception as 6 above during the treatment period and for at least 33 weeks after the last dose of investigational agent.

Exclusion Criteria

•1\. Patients with cT4 of bladder cancer, UTUC or urethra cancer 2\. Hydronephrosis. Patients with hydronephrosis derived from TURBT are eligible for this study. 3\. Breastfeeding and pregnancy 4\. Malignancies within 5 years prior to enrollment other than as follow: 1\) Bladder cancer and UTUC as tumor stage of below pTa/pTis 2\) Localized malignancy treated with expected curative intent 5\. Active or history of autoimmune disease include suspected 6\. Patients have a disease that needs treatment with systemic corticosteroids or other systemic immunosuppressive medications within 14 days prior to the first dose of investigational agent 7\. Prior treatment with an anti\-PD1, anti\-PDL1, anti\-PDL2 or anti\-CTLA4 therapeutic antibodies (including other therapeutic antibodies or drug specifically targeting T cell costimulation or immune checkpoint pathways) 8\. Previous pelvic radiation therapy 9\. Prior chemotherapy, radiation therapy, biological drug (including BCG intravesical instillation) or treatment with investigational agent. Intravesical chemotherapy (single time) is eligible for this study. 10\. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins 11\. Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the Atezolizumab formulation 12\. Serum albumin \<2\.5 g/dL 13\. Positive test for HIV 14\. Patients with active hepatitis B virus or hepatitis C 15\. Active tuberculosis
•16\. Active or history of interstitial lung disease or pulmonary fibrosis diagnosed by imaging and clinical finding 17\. Sever infections within 4 weeks prior to the first dose of investigational agent 18\. Signs or symptoms of infection within 2 weeks prior to the first dose of investigational agent 19\. Receipt of therapeutic oral or IV antibiotics within 2 weeks prior to the first dose of investigational agent 20\. Significant cardiovascular disease 21\. Intractable infection, inflammation disease in irradiation region on study registration Or patients who have an inflammation disease needs systemic treatment 22\. Uncontrolled diabetes mellitus 23\. Major surgical procedure other than for diagnosis within 4 weeks prior the first dose of investigational agent or anticipation of need for a major surgical procedure during the course of the study 24\. Prior allogeneic stem cell or solid organ transplant 25\. Administration of a live, attenuated vaccine within 4 weeks before the first dose of investigational agent or anticipation that such a live ,attenuated vaccine will be required during the study 26\. Treatment with systemic immunostimulatory agents within 6 weeks or five half\-lives of the drug, whichever is shorter, prior to the first dose of investigational agent 27\. Patients who are judged not eligible for this study by investigators